2,502 research outputs found
Reply
No full textWe thank Dr Spence for his interest in the 2020 International Society of Hypertension (ISH) Global Hypertension Practice Guidelines and highlighting what he considers blind spots in the new guidelines. Specifically, the author is concerned that Liddle syndrome, one of the rare monogenic causes of hypertension is not mentioned and its treatment not appropriately addressed in the 2020 ISH guidelines. Dr Spence provides insightful comments describing the central role of the epithelial sodium channel (ENaC) in Liddle syndrome which is responsible for its clinical features including early onset of salt-sensitive hypertension, hypokalemic metabolic alkalosis, and suppression of both renin and aldosterone secretion. Importantly, Liddle syndrome is associated with increased incidence
of premature cardiovascular and cerebrovascular events and usually unresponsive to mineralocorticoid receptor antagonists
Application of the IS-MP-IA model to the German economy and policy implications
No full textExtending the IS-MP-IA model developed by Romer (2000) and applying the GARCH (Engle, 1982, 2001) methodology, the author finds that equilibrium GDP in Germany is positively affected by stock market performance and real exchange rate appreciation, and negatively influenced by the expected inflation rate, the government deficit/GDP ratio, and the U.S. federal funds rate. The relatively low deficit/GDP ratio of 1.83% in 2003 indicates that its fiscal condition was healthy. However, some other EU members may need to exercise fiscal discipline. Because real appreciation has a positive impact on output, a stronger euro may not be a concern for Germany but may be worried by those EU member nations which depend upon exports to stimulate their economies.
Winning redefined, a new brand positioning for MP Motorsport
No full textMP Motorsport is a talent educating race team participating in the classes below the Formula 1. The problem with the lower classes and therefore MP Motorsport as well is that these classes don’t get much attention and exposure. As a company run by people with passion the branding and positioning is more something that naturally emerged from this passion rather than a series of conscious decisions. This makes it fragile. A more conscious strategy and vision on how MP Motorsport needs to be branded and positioned against their competition that is more than “look how cool racing is” is needed to become more attractive for sponsoring. This report describes the process from analysis to finding the right positioning and an advise for a new brand identity and an implementation plan to help becoming more attractive for sponsoring goals. The analysis done with employees showed a unique characteristic that will help the team to position themselves against the competition; the family atmosphere. This atmosphere is what also characterises their contradictory personality. This personality is on one hand leading and ambitious and on the other hand modest and involved. Competition and stakeholder analysis have been performed to find the right combination of being unique to the competition, desirable for the stakeholders (the fans and sponsors) and builds upon the core strengths of the company. Then using the brand key model, a positioning is made with the essence: Be your best self. The belief, “in everyone hides a talent” and values like “everyone is equal” and “together we succeed” combined with the essence and the positioning resulted in a brand story that describes the feeling MP Motorsport wants to communicate. To manifestate the brand, an advise has been set up for a tone of voice and tone of image. Wrapped in a concept called “winning redefined” this advise is part of the whole implementation plan that should lead the way for the team to implement the newly created brand in short and long term actions. In 3 phases MP Motorsport is advised to start with a clear brand introduction to the target groups Gen Z and potential sponsors. The next phase revolves around creating a community to attract both Gen Z talents and subsequently sponsors to interact with the team and each other. Finally the last phase is long term focused and aims for sustainable growth. In this phase the community is established and can expect various opportunities to discover and develop a whole range of talents, sponsors and gen z are connected to each other via MP Motorsport and the team is able to finance the lower classes without the pressure of the money drivers bring along.Strategic Product Desig
Derivations (MP) and Evaluations (OT)
No full textThe main claim of this paper is that the minimalist framework and optimality theory adopt more or less the same architecture of grammar: both assume that a generator defines a set S of potentially well-formed expressions that can be generated on the basis of a given input, and that there is an evaluator that selects the expressions from S that are actually grammatical in a given language L. The paper therefore proposes a model of grammar in which the strengths of the two frameworks are combined: more specifically, it is argued that the computational system of human language CHL from MP creates a set S of potentially well-formed expressions, and that these are subsequently evaluated in an optimality theoretic fashion.The definitive version of this paper is published in Linguistics in Potsdam 25 (2006).Broekhuis, H. (2006). Derivations (MP) and Evaluations (OT)*. In H. Broekhuis & R. Vogel (Eds), Linguistics in Potsdam 25. Optimality Theory and Minimalism: A possible Convergence? Potsdam : Universitätsverlag PotsdamISBN: 9783939469544 (published book)This research is supported by the Netherlands Organisation of Scientific Research (NWO), grant 276-70-00
Stroom- en sedimentmeting Roompot-Veerse Dam (mp.8), 15 en 22 januari 1996
No full textStroom- en sedimentmeting Roompot-Veerse Dam (mp.8) 15 en 22 januari 1996.Deltawerken, Oosterscheld
May Measurement Month 2019: results of blood pressure screening from 47 countries
No full textThere continues to be an inexorable rise in the death toll due to raised blood pressure (BP) which remains the biggest single contributor to global death and the global burden of disease.1 It is estimated that in 2019 about 19% of all deaths (10.8 million) were due to raised BP, having risen from 9.4 million deaths in 2014.2 Hypertension causes over 50% of cases of heart disease,
stroke, and heart failure3 and it is estimated that about 10% of global healthcare spending arises from raised BP and its complications.4 Moreover, hypertension-mediated organ damage increases risk of severe infections from COVID-19, including risk of death.5 For any of these reasons, it is critical to prevent and, failing that, identify and manage raised BP that appears to differentially affect the most vulnerable groups in society. [...
A novel approach to MP-PIC: Continuum particle model for dense particle flows in fluidized beds
No full textA novel approach to Multiphase-Particle-in-Cell (MP-PIC), called Continuum Particle Model (CPM), is developed for dense gas-particle flows. CPM has high computational speed, comparable to that of MP-PIC, but a robustness and accuracy closer to that of a Discrete Element Model (DEM). The gas phase is treated as a continuum phase and particles are tracked discretely, but particle collisions are modelled by considering the divergence of the continuum particle stress tensor. Details on efficient solution to the model are presented. For comparison, a parametric study is performed for quasi-2D fluidized beds. Comparison of CFD-CPM is made with MP-PIC and CFD-DEM. The particle stress models by Harris and Crighton, and by Srivastava and Sundaresan are tested in our CFD-CPM. Results from CFD-CPM based on the Srivastava and Sundaresan particle stress model show good agreement with CFD-DEM results. We validate our model by comparison with experimental benchmark results from Gopalan et. al. (2016).Complex Fluid Processin
May Measurement Month: results of 12 national blood pressure screening programmes between 2017 and 2019
No full textThe first May Measurement Month (MMM) campaign, a global blood pressure (BP) screening programme, began
in 2017 as an initiative of the International Society of Hypertension.1 Two subsequent annual campaigns have
also been completed in consecutive years2,3 and having had to defer activities due to the COVID-19 pandemic
in 2020 the fourth campaign was run in 2021, the results of which are currently in press. Since its initiation in
2017, volunteers from more than 100 countries have participated.
The aims of MMM have remained consistent from the start—to raise awareness of the importance of the measurement of BP at the individual and population level and to provide a temporary pragmatic solution to
the shortfall in BP screening programmes in countries around the world
Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension
No full textIntroduction: Whether ACE inhibitors (ACEi) or angiotensin II receptor blocker (ARB) therapy should be continued, initiated or ceased in patients with COVID-19 is uncertain. Given the widespread use of ACEi/ARBs worldwide, guidance on the use of these drugs is urgently needed. This prospective meta-analysis aims to pool data from randomised controlled trials (RCTs) to assess the safety and efficacy of ACEi/ARB therapy in adults infected with SARS-CoV-2.
Methods and analysis: RCTs will be eligible if they compare patients with COVID-19 randomised to ACEi/ARB continuation or commencement versuss no ACEi/ARB therapy; study duration ≥14 days; recruitment completed between March 2020 and May 2021. The primary outcome will be all-cause mortality at ≤30 days. Secondary outcomes will include mechanical ventilation, admission to intensive care or cardiovascular events at short-term follow-up (≤30 days) and all-cause mortality at longer-term follow-up (>1 month). Prespecified subgroup analyses will assess the effect of sex; age; comorbidities; smoking status; ethnicity; country of origin on all-cause mortality. A search of ClinicalTrials.gov has been performed, which will be followed by a formal search of trial registers, preprint servers, MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials to identify RCTs that meet inclusion criteria. To date, a search of ClinicalTrials.gov identified 21 potentially eligible trials for this meta-analysis. We will request trial investigators/sponsors to contribute standardised grouped tabular outcome data.
Ethics and dissemination: Ethics approval and informed consent will be the responsibility of the individual RCTs. Dissemination of results will occur by peer-reviewed publication. The results of our analysis can inform public health policy and clinical decision making regarding ACEi/ARB use in patients with COVID-19 on a global scale
Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement
No full textHypertension is often linked with metabolic risk factors that share common pathophysiological pathways. Despite wide-spread availability of multiple drug classes, optimal blood pressure (BP) control remains challenging. Increased central sympathetic outflow is frequently neglected as a critical regulator of both circulatory and metabolic pathways and often remains unopposed therapeutically. Selective imidazoline receptor agonists (SIRAs) effectively reduce BP with a favorable side effect profile compared with older centrally acting antihypertensive drugs. Hard outcome data in hypertension, such as prevention of stroke, heart and kidney diseases, are not available with SIRAs. However, in direct comparisons, SIRAs were as effective as angiotensin-converting enzyme inhibitors, β-blockers, calcium channel blockers, and diuretics in lowering BP. Other beneficial effects on metabolic parameters in hypertensive patients with concomitant overweight and obesity have been documented with SIRAs. Here we review the existing evidence on the safety and efficacy of moxonidine, a widely available SIRA, compared with common antihypertensive agents and provide a consensus position statement based on inputs from 12 experts from Europe and Australia on SIRAs in hypertension management
- …
